US 11,851,438 B2
1′-cyano nucleoside analogs and methods for treatment of viral infections
Mark J. Bartlett, Castro Valley, CA (US); Daniel H. Byun, Foster City, CA (US); Yifan Deng, Milpitas, CA (US); Jennifer L. Cosman Ellis, Foster City, CA (US); Rao V. Kalla, Cupertino, CA (US); Richard L. Mackman, Millbrae, CA (US); Dustin S. Siegel, Half Moon Bay, CA (US); and Xianhuang Zeng, Redwood City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Mar. 6, 2023, as Appl. No. 18/117,878.
Application 18/117,878 is a continuation of application No. 18/115,955, filed on Mar. 1, 2023.
Claims priority of provisional application 63/434,993, filed on Dec. 23, 2022.
Claims priority of provisional application 63/424,083, filed on Nov. 9, 2022.
Claims priority of provisional application 63/390,421, filed on Jul. 19, 2022.
Claims priority of provisional application 63/315,769, filed on Mar. 2, 2022.
Prior Publication US 2023/0279014 A1, Sep. 7, 2023
Int. Cl. A61K 31/341 (2006.01); C07D 307/20 (2006.01); C07D 487/04 (2006.01); A61P 31/14 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 31/14 (2018.01)] 16 Claims
 
1. A compound of the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
2. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and the compound of claim 1, or a pharmaceutically acceptable salt thereof.